


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:49:37Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406323" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406323</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>jenzimc</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="pmc-domain-id">3428</journal-id><journal-id journal-id-type="pmc-domain">jenzimc</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406323</article-id><article-id pub-id-type="pmcid-ver">PMC12406323.1</article-id><article-id pub-id-type="pmcaid">12406323</article-id><article-id pub-id-type="pmcaiid">12406323</article-id><article-id pub-id-type="pmid">40891353</article-id><article-id pub-id-type="doi">10.1080/14756366.2025.2551970</article-id><article-id pub-id-type="publisher-id">2551970</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Inhibition mechanism and behaviour of wedelolactone against &#945;-glucosidase</article-title><alt-title alt-title-type="left-running-head">J. Zhang et al.</alt-title><alt-title alt-title-type="right-running-head">Journal of Enzyme Inhibition and Medicinal Chemistry</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3313-2387</contrib-id><name name-style="western"><surname>Zhang</surname><given-names initials="J">Jianjun</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="AF0001" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="M">Min</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="AF0001" ref-type="aff"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0000-6015-8158</contrib-id><name name-style="western"><surname>Wu</surname><given-names initials="F">Fan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="AF0001" ref-type="aff"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6422-6461</contrib-id><name name-style="western"><surname>Shi</surname><given-names initials="Z">Zheng</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="AF0001" ref-type="aff"/><xref rid="AN0002" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0910-5701</contrib-id><name name-style="western"><surname>Xie</surname><given-names initials="R">Rui</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="AF0001" ref-type="aff"/><xref rid="AN0003" ref-type="corresp"/></contrib><aff id="AF0001"><institution>Department of Pharmacy, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine)</institution>, <city>Hangzhou</city>, <country>China</country></aff></contrib-group><author-notes><corresp id="AN0002"><bold>CONTACT </bold>Zheng Shi <email xlink:href="mailto:shizheng@zcmu.edu.cn">shizheng@zcmu.edu.cn</email></corresp><corresp id="AN0003">Rui Xie <email xlink:href="mailto:20173188@zcmu.edu.cn">20173188@zcmu.edu.cn</email><institution>Department of Pharmacy, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine)</institution>, <city>Hangzhou</city>, <postal-code>310006</postal-code>, <country>China</country>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>40</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">478722</issue-id><elocation-id>2551970</elocation-id><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event><event event-type="received"><date><day>12</day><month>6</month><year>2025</year></date></event><event event-type="revised"><date><day>7</day><month>8</month><year>2025</year></date></event><event event-type="accepted"><date><day>19</day><month>8</month><year>2025</year></date></event><event event-type="tagger"><event-desc>KnowledgeWorks Global Ltd.</event-desc><date><day>2</day><month>9</month><year>2025</year></date></event><event event-type="build-issue-online"><event-desc>published online in a building issue</event-desc><date><day>2</day><month>9</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="IENZ_40_2551970.pdf"/><self-uri content-type="pdf" xlink:href="IENZ_40_2551970.pdf"/><abstract><title>Abstract</title><p>The quest for effective and safe treatments for diabetes mellitus has led to the exploration of natural metabolites as potential &#945;-glucosidase inhibitors. This study delves into the inhibition mechanism of wedelolactone against &#945;-glucosidase and its hypoglycaemic activity. Activity assay results discovered that wedelolactone functioned as a mixed-type inhibitor, with an IC<sub>50</sub> of 39.12&#8201;&#177;&#8201;2.54&#8201;&#956;M, surpassing the potency of the standard drug acarbose. Employing multi-spectra methods, our findings indicated that wedelolactone binding induced conformation changes in &#945;-glucosidase to attenuate its enzymatic activity, as evidenced by fluorescence quenching, synchronous fluorescence, 3D fluorescence, CD spectra, and ANS assay. Molecular docking studies provided insights into the specific interactions between wedelolactone and &#945;-glucosidase. Collectively, these results laid the groundwork for the potential application of wedelolactone as a natural therapeutic agent in diabetes management.</p></abstract><abstract abstract-type="graphical"><title>GRAPHICAL ABSTRACT</title><fig position="anchor" id="UF0001" orientation="portrait"><graphic content-type="color" position="float" orientation="portrait" xlink:href="IENZ_A_2551970_UF0001_C.jpg"/></fig></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Wedelolactone</kwd><kwd>&#945;-Glucosidase</kwd><kwd>inhibition mechanism</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution-wrap><institution>Zhejiang Medical and Health Science and Technology Plan Project of China</institution></institution-wrap></funding-source><award-id>2022KY231</award-id></award-group><award-group><funding-source><institution-wrap><institution>Joint Funds of the Zhejiang Provincial Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>LYY21H300002</award-id></award-group><funding-statement>This research was supported by the Zhejiang Medical and Health Science and Technology Plan Project of China (No. 2022KY231) and the Joint Funds of the Zhejiang Provincial Natural Science Foundation of China under Grant (No. LYY21H300002).</funding-statement></funding-group></support-group><counts><fig-count count="10"/><table-count count="3"/><page-count count="12"/><word-count count="4863"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" disp-level="1" id="S0001"><title>Introduction</title><p>Diabetes mellitus (DM), a metabolic disorder of growing global concern, has seen a staggering rise in its prevalence<xref rid="CIT0001" ref-type="bibr"><sup>1&#8211;3</sup></xref>. Epidemiological analysis estimates that approximately 425 million adults are currently living with DM, and DM numbers would increase to around 700 million by 2045<xref rid="CIT0004" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="CIT0005" ref-type="bibr"><sup>5</sup></xref>. Persistent hyperglycaemia, a hallmark of DM, lead to significant internal environmental disruptions, metabolic anomalies, and a myriad of complications<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="CIT0007" ref-type="bibr"><sup>7</sup></xref>. Notably, the correlation between chronic hyperglycaemia and elevated mortality rates has been observed<xref rid="CIT0008" ref-type="bibr"><sup>8&#8211;10</sup>.</xref></p><p>In the therapeutic landscape of type 2&#8201;DM (T2DM), a variety of chemical inhibitors have been sanctioned for clinical use. Among these, &#945;-glucosidase inhibitors have garnered attention for their cost-effectiveness and therapeutic efficacy<xref rid="CIT0011" ref-type="bibr"><sup>11&#8211;13</sup></xref>. &#945;-Glucosidase, an enzyme bound to the intestinal epithelium, facilitates the hydrolysis of glycosidic bond from carbohydrate substrates<xref rid="CIT0014" ref-type="bibr"><sup>14&#8211;16</sup></xref>. This enzyme plays a pivotal role in carbohydrate digestion post-ingestion, converting them into absorbable glucose, which is intrinsically linked to the rise in blood glucose levels. Therefore, inhibition of &#945;-glucosidase can delay the digestion and absorption of dietary carbohydrates, mitigating postprandial hyperglycaemia<xref rid="CIT0017" ref-type="bibr"><sup>17&#8211;19</sup></xref>. There are some &#945;-glucosidase inhibitors in clinical practice, like acarbose. Although acarbose has been proven the efficacy in inhibiting &#945;-glucosidase, it may lead to the accumulation of undigested carbohydrates and the production of gas after fermentation by colonic bacteria. This has stimulated the pursuit of potential &#945;-glucosidase inhibitors derived from natural sources, which may enhance therapeutic efficacy while minimising adverse reactions<xref rid="CIT0020" ref-type="bibr"><sup>20&#8211;22</sup>.</xref></p><p>Wedelolactone (<xref rid="F0001" ref-type="fig">Figure 1</xref>), one important metabolite of edible plant <italic toggle="yes">Eclipta prostrata</italic> L. in south China, has received a lot of attention due to its positive bioactive properties<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref>. Especially its inherent activities inducing antioxidant, anti-tumor, and anti-inflammatory make wedelolactone have the capable of serving as a human health supplement<xref rid="CIT0025" ref-type="bibr"><sup>25&#8211;27</sup></xref>. Previous studies also have revealed that wedelolactone possesses inhibitory activity against &#945;-glucosidase<xref rid="CIT0028" ref-type="bibr"><sup>28</sup></xref>. In this context, the natural metabolite wedelolactone, abundant in food plants, has emerged as a promising candidate for its potential &#945;-glucosidase inhibitory property. However, the detailed inhibitory activity and mechanism of wedelolactone against &#945;-glucosidase and its hypoglycaemic activity were still not invesitgated.</p><fig position="float" id="F0001" orientation="portrait"><label>Figure 1.</label><caption><p>Chemical structure of wedelolactone.</p></caption><graphic content-type="color" position="float" orientation="portrait" xlink:href="IENZ_A_2551970_F0001_C.jpg"/></fig><p>This study delves into the inhibitory effects of wedelolactone on &#945;-glucosidase using multi-spectroscopic and docking methods. The findings aim to elucidate the underlying mechanisms of wedelolactone&#8217;s action against &#945;-glucosidase and its implications for diabetes management.</p></sec><sec sec-type="materials" disp-level="1" id="S0002"><title>Materials and methods</title><sec disp-level="2" id="S0002-S2001"><title>Materials</title><p>Wedelolactone (purity 98%) was procured from Macklin. &#945;-Glucosidase from <italic toggle="yes">Saccharomyces cerevisiae</italic> and p-Nitrophenyl-&#945;-<italic toggle="yes">D</italic>-galactopyranoside (pNPG) were obtained from Sigma-Aldrich. Other reagents were of analytical grade.</p></sec><sec disp-level="2" id="S0002-S2002"><title>Anti-&#945;-glucosidase activity</title><p>In this study, the capacity of wedelolactone to inhibit &#945;-glucosidase was assessed based on previous methods<xref rid="CIT0029" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="CIT0030" ref-type="bibr"><sup>30</sup></xref>. The assay was conducted by mixing &#945;-glucosidase (10&#8201;&#956;L) with varying concentrations of wedelolactone (10&#8201;&#956;L, 8&#8211;128&#8201;&#956;M) into 130&#8201;&#956;L of PBS, followed by incubation for 10&#8201;min at 37&#8201;&#176;C. Subsequently, 50&#8201;&#956;L of substrate pNPG was introduced to above mixture and measured the absorbance at wavelength of 405&#8201;nm.</p></sec><sec disp-level="2" id="S0002-S2003"><title>Inhibitory kinetic</title><sec disp-level="3" id="S0002-S2003-S3001"><title>Reversibility</title><p>To assay reversibility, reaction rate was plotted towards &#945;-glucosidase concentration<xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="CIT0032" ref-type="bibr"><sup>32</sup></xref>. Then, wedelolactone concentration was set to 0&#8201;&#8764;&#8201;64&#8201;&#956;M, pNPG volume was maintained, and &#945;-glucosidase volume was set to 7.5&#8201;&#8764;&#8201;12.5&#8201;&#956;l, respectively.</p></sec><sec disp-level="3" id="S0002-S2003-S3002"><title>Kinetics</title><p>Lineweaver-Burk plots revealed the inhibition kinetics<xref rid="CIT0033" ref-type="bibr"><sup>33</sup></xref><sup>,</sup><xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref>. Samely, wedelolactone concentration was set to 0&#8201;&#8764;&#8201;64&#8201;&#956;M, &#945;-glucosidase volume was maintained, and pNPG concentration was added, respectively.</p></sec></sec><sec disp-level="2" id="S0002-S2004"><title>Fluorescence spectra</title><p>Fluorescence spectra were conducted to assay the interaction between wedelolactone and &#945;-glucosidase<xref rid="CIT0035" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="CIT0036" ref-type="bibr"><sup>36</sup></xref>. Fluorescence spectra of &#945;-glucosidase free or with wedelolactone were recorded at 304, 307, and 310&#8201;K with excitation wavelength of 280&#8201;nm and slit width of 5.0&#8201;nm. &#945;-Glucosidase was added wedelolactone and then measured fluorescence spectra. Moreover, synchronous and 3D fluorescence spectra of mixture were similarly assayed<xref rid="CIT0037" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="CIT0038" ref-type="bibr"><sup>38</sup>.</xref></p></sec><sec disp-level="2" id="S0002-S2005"><title>CD spectra</title><p>CD spectra of &#945;-glucosidase free were determined with scanning wavelength of 190&#8211;260&#8201;nm. Then &#945;-glucosidase was added wedelolactone and measured CD spectra. CDNN software was used to calculate the secondary structure.</p></sec><sec disp-level="2" id="S0002-S2006"><title>ANS</title><p>Fluorescence spectra of ANS-&#945;-glucosidase mixture free or with wedelolactone were determined at excitation wavelength of 350&#8201;nm. 1&#8201;&#181;L of wedelolactone was continuously added into 2&#8201;ml of mixture of ANS-&#945;-glucosidase mixture (0.1&#8201;mg/mL) and recorded fluorescence spectra<xref rid="CIT0039" ref-type="bibr"><sup>39</sup>.</xref></p></sec><sec disp-level="2" id="S0002-S2007"><title>Molecular docking</title><p>Molecular docking between wedelolactone and &#945;-glucosidase was conducted using SYBYL software<xref rid="CIT0040" ref-type="bibr"><sup>40&#8211;43</sup></xref>. Wedelolactone structure was optimised with adding hydrogen, adding charge, and minimising energy. Homologous &#945;-glucosidase was conducted according to previous reports<xref rid="CIT0015" ref-type="bibr"><sup>15</sup></xref>. In brief, the homology modes were built using modeller 10.1 software (<ext-link xlink:href="http://salilab.org/modeller/" ext-link-type="uri">http://salilab.org/modeller/</ext-link>), and the generated modes was verified the quality using Ramachandran plot (<ext-link xlink:href="http://services.mbi.ucla.edu/PROCHECK/" ext-link-type="uri">http://services.mbi.ucla.edu/PROCHECK/</ext-link>). Then, the most reasonable homology mode was selected for docking. Then &#945;-glucosidase also was optimised with removing water, adding hydrogen, and adding charge, followed by generation of active pocket. Then, docking was simulated in default program.</p></sec></sec><sec sec-type="results" disp-level="1" id="S0003"><title>Results and discussion</title><sec disp-level="2" id="S0003-S2001"><title>Inhibitory activity of wedelolactone</title><p>Our investigation results of wedelolactone&#8217;s effect on &#945;-glucosidase (<xref rid="F0002" ref-type="fig">Figure 2</xref>) unveiled its effective inhibitory potential that was directly proportional to the concentration of wedelolactone. Wedelolactone (128&#8201;&#956;M) resulted in about 90% inhibition against &#945;-glucosidase. The IC<sub>50</sub> value of wedelolactone was calculated to be 39.12&#8201;&#177;&#8201;2.54&#8201;&#956;M, which was remarkable lower than that of positive control acarbose (674.62&#8201;&#177;&#8201;10.34&#8201;&#956;M).</p><fig position="float" id="F0002" orientation="portrait"><label>Figure 2.</label><caption><p>Inhibition rate of wedelolactone.</p></caption><graphic content-type="color" position="float" orientation="portrait" xlink:href="IENZ_A_2551970_F0002_C.jpg"/></fig></sec><sec disp-level="2" id="S0003-S2002"><title>Inhibition kinetics</title><p>The reversibility of wedelolactone was confirmed by observing the reaction velocity at varying concentrations of &#945;-glucosidase (<xref rid="F0003" ref-type="fig">Figure 3A</xref>). The linear plots of reaction velocity against &#945;-glucosidase concentration demonstrated that the inhibition was reversible. The kinetic interaction between wedelolactone and &#945;-glucosidase was elucidated using Lineweaver-Burk plot (<xref rid="F0003" ref-type="fig">Figure 3B</xref>). The enzyme kinetics graphical representation provided the clear evidence of a mixed-type inhibition<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref>, which was characterised by the intersection of Lineweaver-Burk plots in the second quadrant.</p><fig position="float" id="F0003" orientation="portrait"><label>Figure 3.</label><caption><p>(A) Reversibility assay of wedelolactone; (B) Kinetics assay of wedelolactone.</p></caption><graphic content-type="color" position="float" orientation="portrait" xlink:href="IENZ_A_2551970_F0003_C.jpg"/></fig><p>The kinetic parameters were further deduced from the slopes (<xref rid="F0004" ref-type="fig">Figure 4A</xref>) and intercepts (<xref rid="F0004" ref-type="fig">Figure 4B</xref>) of Lineweaver-Burk plots, yielding the K<sub>i</sub> value of 0.03&#8201;mM and K<sub>is</sub> value of 0.11&#8201;mM.</p><fig position="float" id="F0004" orientation="portrait"><label>Figure 4.</label><caption><p>(A) K<sub>i</sub> assay of wedelolactone; (B) K<sub>is</sub> assay of wedelolactone.</p></caption><graphic content-type="color" position="float" orientation="portrait" xlink:href="IENZ_A_2551970_F0004_C.jpg"/></fig></sec><sec disp-level="2" id="S0003-S2003"><title>Fluorescence quenching</title><p>The interaction between wedelolactone and &#945;-glucosidase was further explored through fluorescence quenching studies. The intrinsic fluorescence of &#945;-glucosidase was monitored in the presence of &#173;wedelolactone. Our observations revealed fluorescence intensity of &#945;-glucosidase at the characteristic emission peak of 340&#8201;nm gradually declined with the introducing wedelolactone at 304, 307, and 310&#8201;K (<xref rid="F0005" ref-type="fig">Figure 5A&#8211;C</xref>). These phenomena indicated the binding event between &#945;-glucosidase and wedelolactone. Moreover, blue-shifts in &#945;-glucosidase fluorescence peak were also observed, suggesting conformation alteration within the &#945;-glucosidase&#8217;s structure.</p><fig position="float" id="F0005" orientation="portrait"><label>Figure 5.</label><caption><p>(A&#8211;C) Fluorescence quenching assay of wedelolactone at 304, 307, and 310&#8201;K (curve a: wedelolactone only; curve b to n: &#945;-glucosidase with wedelolactone (0.5&#8201;&#8764;&#8201;6&#8201;&#956;M)); (D) The Stern-Volmer plots of wedelolactone.</p></caption><graphic content-type="color" position="float" orientation="portrait" xlink:href="IENZ_A_2551970_F0005_C.jpg"/></fig><p>The Stern-Volmer plots (<xref rid="F0005" ref-type="fig">Figure 5D</xref>), constructed at varying temperatures (304, 307, and 310&#8201;K), demonstrated a linear relationship, signifying a single quenching process. The calculated quenching rate constant (K<sub>q</sub>) values (<xref rid="t0001" ref-type="table">Table 1</xref>) at the respective temperatures were significantly higher than the maximum diffusion collision quenching rate constant (2&#8201;&#215;&#8201;10<sup>10</sup>&#8201;mol L<sup>&#8722;1</sup>S<sup>&#8722;1</sup>), supporting a static quenching of wedelolactone, although Stern-Volmer quenching constant (K<sub>sv</sub>) values decreased with temperature (<xref rid="t0001" ref-type="table">Table 1</xref>). In addition, the association constant (Ka) values (<xref rid="t0001" ref-type="table">Table 1</xref>) were found to be higher than 10<sup>4</sup>, reflecting the stability of the enzyme-inhibitor complex. The binding site number (n) values (<xref rid="t0001" ref-type="table">Table 1</xref>) were all approximately equal to 1, suggesting only one binding site for wedelolactone on &#945;-glucosidase.</p><table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1.</label><caption><p>Fluorescence quenching parameters of wedelolactone.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">T (K)</th><th align="center" colspan="1" rowspan="1">K<sub>q</sub> (&#215; 10<sup>12</sup> Lmol<sup>&#8722;1</sup>S<sup>&#8722;1</sup>)</th><th align="center" colspan="1" rowspan="1">KSV (&#215; 10<sup>4</sup> Lmol<sup>&#8722;1</sup>)</th><th align="center" colspan="1" rowspan="1">K<sub>a</sub> (&#215; 10<sup>4</sup> Lmol<sup>&#8722;1</sup>)</th><th align="center" colspan="1" rowspan="1">n</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">304</td><td align="char" char="." colspan="1" rowspan="1">7.52</td><td align="char" char="." colspan="1" rowspan="1">7.52</td><td align="char" char="." colspan="1" rowspan="1">24.31</td><td align="char" char="." colspan="1" rowspan="1">1.10</td></tr><tr><td align="left" colspan="1" rowspan="1">307</td><td align="char" char="." colspan="1" rowspan="1">9.09</td><td align="char" char="." colspan="1" rowspan="1">9.09</td><td align="char" char="." colspan="1" rowspan="1">16.21</td><td align="char" char="." colspan="1" rowspan="1">1.05</td></tr><tr><td align="left" colspan="1" rowspan="1">310</td><td align="char" char="." colspan="1" rowspan="1">10.00</td><td align="char" char="." colspan="1" rowspan="1">10.00</td><td align="char" char="." colspan="1" rowspan="1">7.33</td><td align="char" char="." colspan="1" rowspan="1">0.97</td></tr></tbody></table></table-wrap></sec><sec disp-level="2" id="S0003-S2004"><title>Thermodynamic analysis</title><p>Thermodynamic parameters in the interaction of wedelolactone and &#945;-glucosidase were further obtained from fluorescence quenching plots using the van&#8217;t Hoff equation. The negative &#916;G and &#916;H values (<xref rid="t0002" ref-type="table">Table 2</xref>) indicated a spontaneous and exothermic binding process. Besides, negative &#916;H and &#916;S values (<xref rid="t0002" ref-type="table">Table 2</xref>) indicated both hydrogen bonds and van der Waals forces as the main binding forces between &#945;-glucosidase and wedelolactone.</p><table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2.</label><caption><p>Thermodynamic parameters of wedelolactone.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">T (K)</th><th align="center" colspan="1" rowspan="1">&#916;H (KJ/moL)</th><th align="center" colspan="1" rowspan="1">&#916;G (KJ/moL)</th><th align="center" colspan="1" rowspan="1">&#916;S (J/(mol&#183;K)</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">304</td><td rowspan="3" align="char" char="." colspan="1">&#8722;104.77</td><td align="char" char="." colspan="1" rowspan="1">&#8722;8.07</td><td rowspan="3" align="char" char="." colspan="1">&#8722;318.10</td></tr><tr><td align="left" colspan="1" rowspan="1">307</td><td align="char" char="." colspan="1" rowspan="1">&#8722;7.11</td></tr><tr><td align="left" colspan="1" rowspan="1">310</td><td align="char" char="." colspan="1" rowspan="1">&#8722;6.16</td></tr></tbody></table></table-wrap></sec><sec disp-level="2" id="S0003-S2005"><title>Synchronous fluorescence spectra</title><p>The synchronous fluorescence was employed to probe fluorophores micro-environmental changes within &#945;-glucosidase upon interaction with wedelolactone. Our investigation focused on the spectral shifts at &#916;<italic toggle="yes">&#955;</italic> of 15 and 60&#8201;nm, indicating the microenvironments alterations surrounding tyrosine and tryptophan residues, respectively. As observed that the fluorescence intensities of these residues in &#945;-glucosidase diminish with increasing concentrations of wedelolactone (<xref rid="F0006" ref-type="fig">Figure 6A and B</xref>). Especially, the characteristic peak of tyrosine residues exhibited slight blue-shift, while that of tryptophan residues unchanged. The decrease in intensity coupling with spectral shift provided the evidence of interaction of wedelolactone with &#945;-glucosidase.</p><fig position="float" id="F0006" orientation="portrait"><label>Figure 6.</label><caption><p>(A&#8211;B) Synchronous fluorescence spectra of wedelolactone with &#916;<italic toggle="yes">&#955;</italic> of 15 and 60&#8201;nm.</p></caption><graphic content-type="color" position="float" orientation="portrait" xlink:href="IENZ_A_2551970_F0006_C.jpg"/></fig></sec><sec disp-level="2" id="S0003-S2006"><title>3D fluorescence spectra</title><p>The conformation changes of &#945;-glucosidase in response to wedelolactone were investigated using 3D fluorescence spectra. Our examination focused on the two characteristic peaks, Peak 1 predominantly reflecting spectral attributes of tryptophan and tyrosine residues and Peak 2 attributed to the &#960;&#8594;&#960;* transitions within the polypeptide backbone. Upon the introduction of wedelolactone, a discernible decrease in the intensity of Peak 1 was recorded (<xref rid="F0007" ref-type="fig">Figure 7</xref>), suggesting the microenvironment alteration surrounding aromatic residues. Furthermore, the intensity of Peak 2 also exhibited a decline (<xref rid="F0006" ref-type="fig">Figure 6</xref>), implying a profound impact on the secondary structure of &#945;-glucosidase.</p><fig position="float" id="F0007" orientation="portrait"><label>Figure 7.</label><caption><p>(A-B) 3D fluorescence spectra of &#945;-glucosidase and &#945;-glucosidase-wedelolactone.</p></caption><graphic content-type="color" position="float" orientation="portrait" xlink:href="IENZ_A_2551970_F0007_C.jpg"/></fig></sec><sec disp-level="2" id="S0003-S2007"><title>CD spectra</title><p>The secondary structure of &#945;-glucosidase was scrutinised in the presence of wedelolactone using CD spectra. &#945;-Glucosidase exhibited characteristic CD negative bands around 212&#8201;&#8764;&#8201;222&#8201;nm, indicative of &#945;-helices structure (<xref rid="F0008" ref-type="fig">Figure 8</xref>). While, upon the addition of wedelolactone, a noticeable reduction in the intensities of these bands was observed (<xref rid="F0008" ref-type="fig">Figure 8</xref>), pointing towards conformation changes in &#945;-glucosidase. As wedelolactone increased, there was a decrease in &#945;-helix content, accompanied by increases in &#946;-sheet, &#946;-turn and random coil contents (<xref rid="t0003" ref-type="table">Table 3</xref>), which was consistent with the results that cryptolepine affected &#945;-glucosidase conformation<xref rid="CIT0005" ref-type="bibr"><sup>5</sup>.</xref></p><fig position="float" id="F0008" orientation="portrait"><label>Figure 8.</label><caption><p>CD spectra of &#945;-glucosidase and &#945;-glucosidase-wedelolactone.</p></caption><graphic content-type="color" position="float" orientation="portrait" xlink:href="IENZ_A_2551970_F0008_C.jpg"/></fig><table-wrap position="float" id="t0003" orientation="portrait"><label>Table 3.</label><caption><p>The secondary structure contents of &#945;-glucosidase by wedelolactone.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Molar ratio</th><th align="center" colspan="1" rowspan="1">&#945;-Helix (%)</th><th align="center" colspan="1" rowspan="1">&#946;-Sheet (%)</th><th align="center" colspan="1" rowspan="1">&#946;-Turn (%)</th><th align="center" colspan="1" rowspan="1">Random Coil (%)</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">1:0</td><td align="char" char="." colspan="1" rowspan="1">21.7</td><td align="char" char="." colspan="1" rowspan="1">38.0</td><td align="char" char="." colspan="1" rowspan="1">19.9</td><td align="char" char="." colspan="1" rowspan="1">40.0</td></tr><tr><td align="left" colspan="1" rowspan="1">1:1</td><td align="char" char="." colspan="1" rowspan="1">20.8</td><td align="char" char="." colspan="1" rowspan="1">40.6</td><td align="char" char="." colspan="1" rowspan="1">20.1</td><td align="char" char="." colspan="1" rowspan="1">40.8</td></tr><tr><td align="left" colspan="1" rowspan="1">1:2</td><td align="char" char="." colspan="1" rowspan="1">20.1</td><td align="char" char="." colspan="1" rowspan="1">42.8</td><td align="char" char="." colspan="1" rowspan="1">20.3</td><td align="char" char="." colspan="1" rowspan="1">41.6</td></tr></tbody></table></table-wrap></sec><sec disp-level="2" id="S0003-S2008"><title>ANS assay</title><p>ANS assay was conducted to investigate the binding of protein and ligand on the hydrophobic environment. As shown in <xref rid="F0009" ref-type="fig">Figure 9A</xref> that, fluorescence peak of ANS-&#945;-glucosidase was at a relative low level, while, that could be obviously increased by wedelolactone addition, accompanied by a blue shift from 510 to 500&#8201;nm. From <xref rid="F0009" ref-type="fig">Figure 9B</xref>, wedelolactone addition (0.5&#8201;&#956;M) would cause an increase in fluorescence intensity by 26.8%.</p><fig position="float" id="F0009" orientation="portrait"><label>Figure 9.</label><caption><p>(A) ANS assay of &#945;-glucosidase with wedelolactone; (B) Fluorescence peak intensity against wedelolactone.</p></caption><graphic content-type="color" position="float" orientation="portrait" xlink:href="IENZ_A_2551970_F0009_C.jpg"/></fig></sec><sec disp-level="2" id="S0003-S2009"><title>Docking analysis</title><p>The molecular underpinnings of wedelolactone&#8217;s interaction with &#945;-glucosidase were elucidated through molecular docking. After docking procedure, the most stable pose of wedelolactone was selected was chosen to analyse. As shown in <xref rid="F0010" ref-type="fig">Figure 10A</xref>, wedelolactone nestled within the active pocket of &#945;-glucosidase with a binding energy of &#8722;4.1&#8201;kcal/mol. Furthermore, wedelolactone not only formed hydrogen bonds with key amino acid residues Arg212, Asp214, and Gln350, but also made hydrophobic interactions with Phe300 and Asp349 (<xref rid="F0010" ref-type="fig">Figure 10B</xref>).</p><fig position="float" id="F0010" orientation="portrait"><label>Figure 10.</label><caption><p>(A-B) Docking of wedelolactone with &#945;-glucosidase.</p></caption><graphic content-type="color" position="float" orientation="portrait" xlink:href="IENZ_A_2551970_F0010_C.jpg"/></fig></sec></sec><sec sec-type="discussion" disp-level="1" id="S0004"><title>Discussion</title><p>Natural products have the characteristics of diverse molecular structures<xref rid="CIT0044" ref-type="bibr"><sup>44&#8211;46</sup></xref>, rich pharmacological activities<xref rid="CIT0047" ref-type="bibr"><sup>47&#8211;49</sup></xref>, and low toxicity<xref rid="CIT0050" ref-type="bibr"><sup>50&#8211;52</sup></xref>, making them as an important source of clinical drugs. With the processing of scientific research on diabetes pathogenesis, natural product development, and people&#8217;s demand for safe medicine, natural products as &#945;-glucosidase inhibitors for diabetes treatment have received growing attention<xref rid="CIT0053" ref-type="bibr"><sup>53&#8211;55</sup>.</xref></p><p>Due to the low toxicity and multi-activity, wedelolactone was investigated &#945;-glucosidase inhibition mechanism using multi-spectroscopic and docking methods. Our results demonstrated that wedelolactone presented its potential on &#945;-glucosidase inhibition with IC<sub>50</sub> value of 39.12&#8201;&#177;&#8201;2.54&#8201;&#956;M, &#8764;17-fold stronger than control acarbose (674.62&#8201;&#177;&#8201;10.34&#8201;&#956;M). Inhibition kinetics results revealed wedelolactone as a reversible mixed-type inhibitor, which suggested that wedelolactone bound to &#945;-glucosidase with non-covalent binding, and could bind to free enzymes and enzyme substrate complexes<xref rid="CIT0056" ref-type="bibr"><sup>56</sup></xref>. Then the binding constants (K<sub>i</sub> and K<sub>is</sub>) were calculated, and lower K<sub>i</sub> (0.03&#8201;mM) than K<sub>is</sub> (0.11&#8201;mM) indicated stronger affinity of wedelolactone to free enzyme than the enzyme-substrate complex<xref rid="CIT0057" ref-type="bibr"><sup>57</sup>.</xref></p><p>Subsequently, the effects of wedelolactone on enzyme structure were studied. Fluorescence quenching method is widely used to study the effects of inhibitors on enzyme conformation. Our fluorescence quenching results confirmed the binding of wedelolactone to &#945;-glucosidase would quench endogenous fluorescence of enzymes in the static process, which was evidenced by by linear Stern-Volmer plots and higher K<sub>q</sub> values (higher than 2&#8201;&#215;&#8201;10<sup>10</sup>&#8201;mol L<sup>&#8722;1</sup>S<sup>&#8722;1</sup>). Especially, thermodynamic processes analysis indicated both hydrogen bonds and van der Waals forces as the main binding forces between &#945;-glucosidase and wedelolactone. These similar enzyme quenching phenomena had also been found in other natural products, like quercetin<xref rid="CIT0058" ref-type="bibr"><sup>58</sup></xref> and gallocatechin gallate<xref rid="CIT0059" ref-type="bibr"><sup>59</sup>.</xref></p><p>The effects of wedelolactone on enzyme structure were further assayed by synchronous/3D fluorescence, CD, and ANS spectra. Monitoring synchronous fluorescence spectra of &#945;-glucosidase treated with wedelolactone found that wedelolactone would bind to tyrosine and tryptophan residues to quench enzyme fluorescence, which caused the microenvironment changes around tyrosine and tryptophan residues. 3D fluorescence spectra can response tryptophan and tyrosine residues, and polypeptide backbone. The changed 3D fluorescence spectra of &#945;-glucosidase by wedelolactone revealed that wedelolactone perturbed the spectral characteristics of &#945;-glucosidase, indicating the conformational rearrangements within the enzyme to disrupt the enzyme&#8217;s catalytic activity. CD spectra were used to monitor the secondary structure of &#945;-glucosidase, and our results indicated that the binding of wedelolactone to &#945;-glucosidase caused the changes in secondary structure contents of &#945;-glucosidase, by intercalating into the enzyme&#8217;s internal structure and obstructing the active site, to inhibit its activity. Moreover, the hydrophobicity of &#945;-glucosidase was assayed by monitoring ANS fluorescence, and the increasing ANS fluorescence with the wedelolactone concentration suggested that the binding of wedelolactone would expose enzyme hydrophobic region, then, to reduce the enzyme activity.</p><p>Finally, the binding detail of wedelolactone to &#945;-glucosidase was investigated by molecular docking analysis, and the results found that wedelolactone not only formed hydrogen bonds with key amino acid residues Arg212, Asp214, and Gln350, but also made hydrophobic interactions with Phe300 and Asp349. These interactions contributed to the conformation change of &#945;-glucosidase, thus, inhibiting enzyme activity<xref rid="CIT0060" ref-type="bibr"><sup>60</sup>.</xref></p><p>All above spectra analysis not only corroborated the binding of wedelolactone to &#945;-glucosidase but also provided a deeper understanding of the thermodynamic nature of this interaction.</p></sec><sec sec-type="conclusions" disp-level="1" id="S0005"><title>Conclusion</title><p>In general, we investigated the inhibitory effects of wedelolactone, a bioactive metabolite in <italic toggle="yes">Eclipta prostrata</italic> L., on &#945;-glucosidase and its subsequent hypoglycaemic effects. Activity assay results discovered that wedelolactone functioned as a mixed-type inhibitor, with an IC<sub>50</sub> of 39.12&#8201;&#177;&#8201;2.54&#8201;&#956;M, surpassing the potency of the standard drug acarbose. Employing a multi-spectra method, our findings indicated that wedelolactone binding induced conformation changes in &#945;-glucosidase to attenuate its enzymatic activity, as evidenced by fluorescence quenching, synchronous fluorescence, 3D fluorescence, CD spectra, and ANS assay. Molecular docking studies provided insights into the specific interactions between wedelolactone and &#945;-glucosidase. Collectively, these results laid the groundwork for the potential application of wedelolactone as a natural therapeutic agent in diabetes management. This work only investigated the inhibition mechanism of wedelolactone on &#945;-glucosidase <italic toggle="yes">in vitro</italic>, but did not involve the hypoglycaemic activity in vivo. Thence, further clarification of the hypoglycaemic activity of wedelolactone in vivo will strengthen its application potential as &#945;-glucosidase inhibitor.</p></sec></body><back><sec disp-level="1" id="S0006"><title>Acknowledgements</title><p>Jianjun Zhang: Investigation and Writing-original draft; Min Zhao: Methodology; Fan Wu: Data curation; Zheng Shi: Project administration and Supervision; Rui Xie: Conceptualisation, Funding acquisition and Writing-review &amp; editing.</p></sec><sec sec-type="COI-statement" disp-level="1" id="S0007"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><sec sec-type="data-availability" disp-level="1" id="S0008"><title>Data availability statement</title><p>The datasets presented in current study are available from the corresponding author upon reasonable request.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chai</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhuang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></string-name></person-group><article-title>Projected rapid growth in diabetes disease burden and economic burden in China: a spatio-temporal study from 2020 to 2030</article-title>. <source>Lancet Reg Health West Pac</source>. <year>2023</year>;<volume>33</volume>:<fpage>100700</fpage>.<pub-id pub-id-type="pmid">36817869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lanwpc.2023.100700</pub-id><pub-id pub-id-type="pmcid">PMC9932123</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Deng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></string-name></person-group><article-title>Optogenetic therapeutic strategies for diabetes mellitus</article-title>. <source>J Diabetes</source>. <year>2024</year>;<volume>16</volume>(<issue>6</issue>):<fpage>e13557</fpage>.<pub-id pub-id-type="pmid">38751366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1753-0407.13557</pub-id><pub-id pub-id-type="pmcid">PMC11096815</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Min</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X.</given-names></string-name></person-group><article-title>Identification of 1,3,4-thiadiazolyl-containing thiazolidine-2,4-dione derivatives as novel PTP1B inhibitors with anti-diabetic activity</article-title>. <source>J Med Chem</source>. <year>2024</year>;<volume>67</volume>(<issue>10</issue>):<fpage>8406</fpage>&#8211;<lpage>8419</lpage>.<pub-id pub-id-type="pmid">38723203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.4c00676</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Su</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ouyang</surname><given-names>S.</given-names></string-name></person-group><article-title>Advances in research on type 2 diabetes mellitus targets and therapeutic agents</article-title>. <source>Int J Mol Sci</source>. <year>2023</year>;<volume>24</volume>(<issue>17</issue>):<fpage>13381</fpage>.<pub-id pub-id-type="pmid">37686185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms241713381</pub-id><pub-id pub-id-type="pmcid">PMC10487533</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Min</surname><given-names>XF</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>SQ</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>YJ</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>XT.</given-names></string-name></person-group><article-title>Investigation on the inhibition mechanism and binding behavior of cryptolepine to &#945;-glucosidase and its hypoglycemic activity by multi-spectroscopic method</article-title>. <source>J. Lumin</source>. <year>2024</year>;<volume>269</volume>:<fpage>120437</fpage>.</mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>F.</given-names></string-name></person-group><article-title>Prevalence, awareness and control of type 2 diabetes mellitus and risk factors in Chinese elderly population</article-title>. <source>BMC Public Health</source>. <year>2022</year>;<volume>22</volume>(<issue>1</issue>):<fpage>1382</fpage>.<pub-id pub-id-type="pmid">35854279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12889-022-13759-9</pub-id><pub-id pub-id-type="pmcid">PMC9295461</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jia</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bai</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mather</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hill</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jia</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Sowers</surname><given-names>J.</given-names></string-name></person-group><article-title>Diabetic vasculopathy: molecular mechanisms and clinical insights</article-title>. <source>Int J Mol Sci</source>. <year>2024</year>;<volume>25</volume>(<issue>2</issue>):<fpage>804</fpage>.<pub-id pub-id-type="pmid">38255878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25020804</pub-id><pub-id pub-id-type="pmcid">PMC10815704</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pliszka</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Szablewski</surname><given-names>L.</given-names></string-name></person-group><article-title>Associations between diabetes mellitus and selected cancers</article-title>. <source>Int J Mol Sci</source>. <year>2024</year>;<volume>25</volume>(<issue>13</issue>):<fpage>7476</fpage>.<pub-id pub-id-type="pmid">39000583</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25137476</pub-id><pub-id pub-id-type="pmcid">PMC11242587</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Chivese</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Werfalli</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yuen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hoegfeldt</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Powe</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Immanuel</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Karuranga</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>IDF diabetes atlas: Estimation of global and regional gestational diabetes mellitus prevalence for 2021 by international association of diabetes in pregnancy study group&#8217;s criteria</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2022</year>;<volume>183</volume>:<fpage>109050</fpage>.<pub-id pub-id-type="pmid">34883186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2021.109050</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>K</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Synthesis and anti-&#945;-glucosidase activity evaluation of betulinic acid derivatives</article-title>. <source>Arab J Chem</source>. <year>2023</year>;<volume>16</volume>(<issue>5</issue>):<fpage>104659</fpage>.</mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Luo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>G.</given-names></string-name></person-group><article-title>Novel carbazole-oxadiazole derivatives as anti-&#945;-glucosidase and anti-&#945;-amylase agents: Design, synthesis, molecular docking, and biological evaluation</article-title>. <source>Eur J Med Chem</source>. <year>2024</year>;<volume>275</volume>:<fpage>116600</fpage>.<pub-id pub-id-type="pmid">38889608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2024.116600</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Feng</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Luo</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>G.</given-names></string-name></person-group><article-title>Synthesis, biological evaluation and action mechanism of 7H-[1,2,4] triazolo [3,4-b] [1,3,4] thiadiazine-phenylhydrazone derivatives as &#945;-glucosidase inhibitors</article-title>. <source>Eur J Med Chem</source>. <year>2023</year>;<volume>262</volume>:<fpage>115920</fpage>.<pub-id pub-id-type="pmid">37939444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2023.115920</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X.</given-names></string-name></person-group><article-title>Novel thiosemicarbazide-based &#946;-carboline derivatives as &#945;-glucosidase inhibitors: Synthesis and biological evaluation</article-title>. <source>Eur J Med Chem</source>. <year>2024</year>;<volume>275</volume>:<fpage>116595</fpage>.<pub-id pub-id-type="pmid">38875808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2024.116595</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Singh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kaur</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kaur</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Chadha</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bedi</surname><given-names>P.</given-names></string-name></person-group><article-title>Recent developments in synthetic &#945;-glucosidase inhibitors: A comprehensive review with structural and molecular insight</article-title>. <source>J Mol Struct</source>. <year>2023</year>;<volume>1281</volume>:<fpage>135115</fpage>.</mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S-H</given-names></string-name>, <string-name name-style="western"><surname>Xuetao</surname><given-names>X.</given-names></string-name></person-group><article-title>Synthesis and biological evaluation of indole derivatives containing thiazolidine-2,4-dione as &#945;-glucosidase inhibitors with antidiabetic activity</article-title>. <source>Eur J Med Chem</source>. <year>2024</year>;<volume>264</volume>:<fpage>115957</fpage>.<pub-id pub-id-type="pmid">38029465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2023.115957</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X.</given-names></string-name></person-group><article-title>New &#946;-carboline derivatives as potential &#945;-glucosidase inhibitor: Synthesis and biological activity evaluation</article-title>. <source>J Mol Struct</source>. <year>2023</year>;<volume>1283</volume>:<fpage>135279</fpage>.</mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>L.</given-names></string-name></person-group><article-title>Both acidic pH value and binding interactions of tartaric acid with &#945;-glucosidase cause the enzyme inhibition: The mechanism in &#945;-glucosidase inhibition of four caffeic and tartaric acid derivates</article-title>. <source>Front Nutr</source>. <year>2021</year>;<volume>8</volume>:<fpage>766756</fpage>.<pub-id pub-id-type="pmid">34692755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnut.2021.766756</pub-id><pub-id pub-id-type="pmcid">PMC8529059</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lim</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ferruzzi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hamaker</surname><given-names>B.</given-names></string-name></person-group><article-title>Structural requirements of flavonoids for the selective inhibition of &#945;-amylase versus &#945;-glucosidase</article-title>. <source>Food Chem</source>. <year>2022</year>;<volume>370</volume>:<fpage>130981</fpage>.<pub-id pub-id-type="pmid">34500290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.foodchem.2021.130981</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>MY</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>BW</given-names></string-name>, <string-name name-style="western"><surname>Min</surname><given-names>XF</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>XT.</given-names></string-name></person-group><article-title>Thiazolidine-2,4-dione derivatives as potential &#945;-glucosidase inhibitors: Synthesis, inhibitory activity, binding interaction and hypoglycemic activity</article-title>. <source>Bioorg Chem</source>. <year>2024</year>;<volume>144</volume>:<fpage>107177</fpage>.<pub-id pub-id-type="pmid">38335756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioorg.2024.107177</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mou</surname><given-names>X.</given-names></string-name></person-group><article-title>Acarbose ameliorates spontaneous type-2 diabetes in db/db mice by inhibiting PDX-1 methylation</article-title>. <source>Mol Med Rep</source>. <year>2021</year>;<volume>23</volume>(<issue>1</issue>):<fpage>72</fpage>.<pub-id pub-id-type="pmid">33236139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/mmr.2020.11710</pub-id><pub-id pub-id-type="pmcid">PMC7716388</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>R.</given-names></string-name></person-group><article-title>Predictors of acarbose therapeutic efcacy in newly diagnosed type 2 diabetes mellitus patients in China</article-title>. <source>BMC Pharmacol Toxico</source>. <year>2022</year>;<volume>23</volume>:<fpage>79</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40360-022-00621-2</pub-id><pub-id pub-id-type="pmcid">PMC9580108</pub-id><pub-id pub-id-type="pmid">36258236</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>XZ</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>XT.</given-names></string-name></person-group><article-title>Synthesis and biological evaluation of coumarin derivatives containing oxime ester as &#945;-glucosidase inhibitors</article-title>. <source>Arab J Chem</source>. <year>2022</year>;<volume>15</volume>(<issue>9</issue>):<fpage>104072</fpage>.</mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ha</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Hop</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Son</surname><given-names>N.</given-names></string-name></person-group><article-title>Wedelolactone: A molecule of interests</article-title>. <source>Fitoerapia</source>. <year>2023</year>;<volume>164</volume>:<fpage>105355</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.fitote.2022.105355</pub-id><pub-id pub-id-type="pmid">36410612</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vinyagam</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Matin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>S.</given-names></string-name></person-group><article-title>Biological and functional properties of wedelolactone in human chronic diseases</article-title>. <source>Phyton</source>. <year>2021</year>;<volume>90</volume>(<issue>1</issue>):<fpage>1</fpage>&#8211;<lpage>15</lpage>.</mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>D.</given-names></string-name></person-group><article-title>Effect and mechanism of wedelolactone as antioxidant-coumestan on &#8226;OH-treated mesenchymal stem cells</article-title>. <source>Arab J Chem</source>. <year>2020</year>;<volume>13</volume>(<issue>1</issue>):<fpage>184</fpage>&#8211;<lpage>192</lpage>.</mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>S.</given-names></string-name></person-group><article-title>Studies on the binding of wedelolactone to human serum albumin with multi-spectroscopic analysis, molecular docking and molecular dynamic simulation</article-title>. <source>Biophys Chem</source>. <year>2024</year>;<volume>307</volume>:<fpage>107198</fpage>.<pub-id pub-id-type="pmid">38359582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bpc.2024.107198</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Dou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ye</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Wedelolactone facilitates Ser/Thr phosphorylation of NLRP3 dependent on PKA signalling to block inflammasome activation and pyroptosis</article-title>. <source>Cell Proliferat</source>. <year>2020</year>;<volume>53</volume>:<fpage>e12868</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cpr.12868</pub-id><pub-id pub-id-type="pmcid">PMC7507381</pub-id><pub-id pub-id-type="pmid">32656909</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kumar</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Sharm</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ahmed</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Al-Abbasi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Anwar</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Verma</surname><given-names>A.</given-names></string-name></person-group><article-title>Deconvoluting the dual hypoglycemic effect of wedelolactone isolated from Wedelia calendulacea: investigation via experimental validation and molecular docking</article-title>. <source>RSC Adv</source>. <year>2018</year>;<volume>8</volume>(<issue>32</issue>):<fpage>18180</fpage>&#8211;<lpage>18196</lpage>.<pub-id pub-id-type="pmid">35542112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c7ra12568b</pub-id><pub-id pub-id-type="pmcid">PMC9080591</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>XT</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>XY</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>QM</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>PP</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>ZY</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Synthesis and biological evaluation of coumarin derivatives as &#945;-glucosidase inhibitors</article-title>. <source>Eur J Med Chem</source>. <year>2020</year>;<volume>189</volume>:<fpage>112013</fpage>.<pub-id pub-id-type="pmid">31972390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2019.112013</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kou</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X.</given-names></string-name></person-group><article-title>Novel coumarin-thiazolidine-2,4&#8209;dione hybrids as potential &#945;-glucosidase inhibitors: Synthesis and bioactivity evaluation</article-title>. <source>J Mol Struct</source>. <year>2025</year>;<volume>1322</volume>:<fpage>140481</fpage>.</mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X.</given-names></string-name></person-group><article-title>Novel sulfonyl hydrazide based &#946;-carboline derivatives as potential &#945;-glucosidase inhibitors: design, synthesis, and biological evaluation</article-title>. <source>Mol Divers</source>. <year>2025</year>;<volume>29</volume>(<issue>2</issue>):<fpage>1669</fpage>&#8211;<lpage>1681</lpage>.<pub-id pub-id-type="pmid">39141208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11030-024-10943-4</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>G.</given-names></string-name></person-group><article-title>Chromone-based benzohydrazide derivatives as potential &#945;-glucosidase inhibitor: Synthesis, biological evaluation and molecular docking study</article-title>. <source>Bioorg Chem</source>. <year>2023</year>;<volume>131</volume>:<fpage>106276</fpage>.<pub-id pub-id-type="pmid">36434950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioorg.2022.106276</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Liao</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lei</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>In vitro and in silico studies of bis (indol-3-yl) methane derivatives as potential &#945;-glucosidase and &#945;-amylase inhibitors</article-title>. <source>J Enzym Inhib Med Ch</source>. <year>2021</year>;<volume>36</volume>(<issue>1</issue>):<fpage>1938</fpage>&#8211;<lpage>1951</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14756366.2021.1971976</pub-id><pub-id pub-id-type="pmcid">PMC8409970</pub-id><pub-id pub-id-type="pmid">34459690</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Deng</surname><given-names>XY</given-names></string-name>, <string-name name-style="western"><surname>Ke</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>PP</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>XT.</given-names></string-name></person-group><article-title>Synthesis and bioactivities evaluation of oleanolic acid oxime ester derivatives as &#945;-glucosidase and &#945;-amylase inhibitors</article-title>. <source>J Enzyme Inhib Med Chem</source>. <year>2022</year>;<volume>37</volume>(<issue>1</issue>):<fpage>451</fpage>&#8211;<lpage>461</lpage>.<pub-id pub-id-type="pmid">35012401</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14756366.2021.2018682</pub-id><pub-id pub-id-type="pmcid">PMC8757604</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Feng</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Min</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X.</given-names></string-name></person-group><article-title>Synthesis, anti-&#945;-glucosidase activity, inhibition interaction, and anti-diabetic activity of novel cryptolepine derivatives</article-title>. <source>J Mol Struct</source>. <year>2024</year>;<volume>1310</volume>:<fpage>138311</fpage>.</mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S.</given-names></string-name></person-group><article-title>&#945;-Glucosidase inhibition research of derivatives based on 2&#946;-acetoxyferruginol scaffold excluding acetic acid group</article-title>. <source>Chin J Org Chem</source>. <year>2024</year>;<volume>44</volume>(<issue>2</issue>):<fpage>613</fpage>&#8211;<lpage>621</lpage>.</mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>G.</given-names></string-name></person-group><article-title>Design, synthesis, biological evaluation, and docking study of chromone-based phenylhydrazone and benzoylhydrazone derivatives as antidiabetic agents targeting &#945;-glucosidase</article-title>. <source>Bioorg Chem</source>. <year>2023</year>;<volume>132</volume>:<fpage>106384</fpage>.,<pub-id pub-id-type="pmid">36696731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioorg.2023.106384</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xiao</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>BW</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>XT</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>WH.</given-names></string-name></person-group><article-title>Identification of 1,3,4-oxadiazolyl-containing &#946;-carboline derivatives as novel &#945;-glucosidase inhibitors with antidiabetic activity</article-title>. <source>Eur J Med Chem</source>. <year>2023</year>;<volume>261</volume>:<fpage>115795</fpage>.<pub-id pub-id-type="pmid">37688939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2023.115795</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Fang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X.</given-names></string-name></person-group><article-title>Rosa&#8201;&#215;&#8201;damascena Herrm. essential oil: anti-tyrosinase activity and phytochemical composition</article-title>. <source>Front Pharmacol</source>. <year>2024</year>;<volume>15</volume>:<fpage>1451452</fpage>.<pub-id pub-id-type="pmid">39323629</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2024.1451452</pub-id><pub-id pub-id-type="pmcid">PMC11422205</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Min</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kou</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X.</given-names></string-name></person-group><article-title>Insights into inhibitory action and interaction of bisdemethoxycurcumin on tyrosinase: Spectroscopic and docking analysis</article-title>. <source>Int J Biol Macromol</source>. <year>2024</year>;<volume>281</volume>(<issue>Pt 4</issue>):<fpage>136655</fpage>.<pub-id pub-id-type="pmid">39423987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2024.136655</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Min</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Gan</surname><given-names>L.</given-names></string-name></person-group><article-title>In vitro and In vivo biological evaluation of indole-thiazolidine-2,4-dione derivatives as tyrosinase inhibitors</article-title>. <source>Molecules</source>. <year>2023</year>;<volume>28</volume>(<issue>22</issue>):<fpage>7470</fpage>.<pub-id pub-id-type="pmid">38005192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules28227470</pub-id><pub-id pub-id-type="pmcid">PMC10673563</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Bai</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>H.</given-names></string-name></person-group><article-title>Novel coumarin derivatives as potential tyrosinase inhibitors: Synthesis, binding analysis and biological evaluation</article-title>. <source>Arab. J. Chem</source>. <year>2023</year>;<volume>16</volume>(<issue>6</issue>):<fpage>104724</fpage>.</mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Min</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>J.</given-names></string-name></person-group><article-title>Synthesis, anti-tyrosinase activity, and spectroscopic inhibition mechanism of cinnamic acid-eugenol esters</article-title>. <source>Molecules</source>. <year>2023</year>;<volume>28</volume>(<issue>16</issue>):<fpage>5969</fpage>.<pub-id pub-id-type="pmid">37630220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules28165969</pub-id><pub-id pub-id-type="pmcid">PMC10460039</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X.</given-names></string-name></person-group><article-title>Asymmetric total synthesis and assignment of absolute configuration of arbornamine</article-title>. <source>Org Lett</source>. <year>2020</year>;<volume>22</volume>(<issue>21</issue>):<fpage>8589</fpage>&#8211;<lpage>8592</lpage>.<pub-id pub-id-type="pmid">33104370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.orglett.0c03183</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X.</given-names></string-name></person-group><article-title>Application of tert-butanesulfinamide in total synthesis of natural products</article-title>. <source>Chin J Org Chem</source>. <year>2020</year>;<volume>40</volume>(<issue>12</issue>):<fpage>3991</fpage>&#8211;<lpage>4014</lpage>.</mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X.</given-names></string-name></person-group><article-title>Asymmetric synthesis of (S)-(-)-xylopinine and (S)-(+)-laudanosine</article-title>. <source>Chin J Org Chem</source>. <year>2023</year>;<volume>43</volume>:<fpage>3297</fpage>&#8211;<lpage>3303</lpage>.</mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ke</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S.</given-names></string-name></person-group><article-title>Recent advances on pyrrole synthesis through different annulation modes</article-title>. <source>Chinese J Org Chem</source>. <year>2021</year>;<volume>41</volume>(<issue>1</issue>):<fpage>206</fpage>&#8211;<lpage>228</lpage>.</mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bao</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xiang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>B.</given-names></string-name></person-group><article-title>Design of stable chiral aminosulfonium ylides and their catalytic asymmetric synthesis</article-title>. <source>Angew Chem Int Ed</source>. <year>2024</year>;<volume>63</volume>(<issue>50</issue>):<fpage>e202412508</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.202412508</pub-id><pub-id pub-id-type="pmid">39213133</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sheng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Asiri</surname><given-names>A.</given-names></string-name></person-group><article-title>Synthesis and anti-inflammatory effects of oxaprozin-paeonol ester</article-title>. <source>Chin J Org Chem</source>. <year>2019</year>;<volume>39</volume>(<issue>10</issue>):<fpage>2958</fpage>&#8211;<lpage>2964</lpage>.</mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Qiu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X.</given-names></string-name></person-group><article-title>Diastereoselective synthesis of cycloheptannelated indoles via lewis-acid-catalyzed (4&#8201;+&#8201;3)-cyclization of donor-acceptor cyclopropanes</article-title>. <source>Org Lett</source>. <year>2020</year>;<volume>22</volume>(<issue>5</issue>):<fpage>1903</fpage>&#8211;<lpage>1907</lpage>.<pub-id pub-id-type="pmid">32065751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.orglett.0c00248</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>X-T</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ren</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Y-R</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>Y-Y</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>D-G</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>R-P</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Goodin</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Effects of atorvastatin in combination with celecoxib and tipifarnib on proliferation and apoptosis in pancreatic cancer sphere-forming cells</article-title>. <source>Eur J Pharmacol</source>. <year>2021</year>;<volume>893</volume>:<fpage>173840</fpage>.<pub-id pub-id-type="pmid">33359649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2020.173840</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Min</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></string-name></person-group><article-title>Investigation on the inhibition mechanism and binding behavior of paeonol to tyrosinase and its anti-browning property by multi-spectroscopic and molecular docking methods</article-title>. <source>Int J Biol Macromol</source>. <year>2023</year>;<volume>253</volume>(<issue>Pt 3</issue>):<fpage>126962</fpage>.<pub-id pub-id-type="pmid">37722636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2023.126962</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>L.</given-names></string-name></person-group><article-title>Short-term prediction method of blood glucose based on temporal multi-head attention mechanism for diabetic patients</article-title>. <source>Biomed Signal Proces</source>. <year>2023</year>;<volume>82</volume>:<fpage>104552</fpage>.</mixed-citation></ref><ref id="CIT0054"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M.</given-names></string-name></person-group><article-title>The promise of CRISPR/Cas9 technology in diabetes mellitus therapy: How gene editing is revolutionizing diabetes research and treatment</article-title>. <source>J Diabetes Complications</source>. <year>2023</year>;<volume>37</volume>(<issue>8</issue>):<fpage>108524</fpage>.<pub-id pub-id-type="pmid">37295292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jdiacomp.2023.108524</pub-id></mixed-citation></ref><ref id="CIT0055"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tomic</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Shaw</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Magliano</surname><given-names>D.</given-names></string-name></person-group><article-title>The burden and risks of emerging complications of diabetes mellitus</article-title>. <source>Nat Rev Endocrinol</source>. <year>2022</year>;<volume>18</volume>(<issue>9</issue>):<fpage>525</fpage>&#8211;<lpage>539</lpage>.<pub-id pub-id-type="pmid">35668219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41574-022-00690-7</pub-id><pub-id pub-id-type="pmcid">PMC9169030</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>K</given-names></string-name>, <etal>et al.</etal></person-group><article-title>New chromone derivatives bearing thiazolidine-2,4-dione moiety as potent PTP1B inhibitors: Synthesis and biological activity evaluation</article-title>. <source>Bioorg Chem</source>. <year>2024</year>;<volume>143</volume>:<fpage>106985</fpage>.<pub-id pub-id-type="pmid">38007892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioorg.2023.106985</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wen</surname><given-names>Y.</given-names></string-name></person-group><article-title>Synthesis and biological evaluation of chromonethiazolidine-2,4-dione derivatives as potential &#945;-glucosidase inhibitors</article-title>. <source>Arab. J. Chem</source>. <year>2023</year>;<volume>16</volume>(<issue>11</issue>):<fpage>105279</fpage>.</mixed-citation></ref><ref id="CIT0058"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bian</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Shan</surname><given-names>F.</given-names></string-name></person-group><article-title>Comparative evaluation of quercetin, isoquercetin and rutin as inhibitors of &#945;-glucosidase</article-title>. <source>J Agric Food Chem</source>. <year>2009</year>;<volume>57</volume>(<issue>24</issue>):<fpage>11463</fpage>&#8211;<lpage>11468</lpage>.<pub-id pub-id-type="pmid">19938837</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jf903083h</pub-id></mixed-citation></ref><ref id="CIT0059"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></string-name></person-group><article-title>Exploring inhibitory mechanism of gallocatechin gallate on &#945;-amylase and &#945;-glucosidase relevant to postprandial hyperglycemia</article-title>. <source>J Funct Foods</source>. <year>2018</year>;<volume>48</volume>:<fpage>200</fpage>&#8211;<lpage>209</lpage>.</mixed-citation></ref><ref id="CIT0060"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>J.</given-names></string-name></person-group><article-title>Anti-&#945;-glucosidase, SAR analysis, and mechanism investigation of indolo[1,2-b]isoquinoline derivatives</article-title>. <source>Molecules</source>. <year>2023</year>;<volume>28</volume>(<issue>13</issue>):<fpage>5282</fpage>.<pub-id pub-id-type="pmid">37446942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules28135282</pub-id><pub-id pub-id-type="pmcid">PMC10343752</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>